Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Dow
Harvard Business School
Express Scripts
McKesson

Last Updated: June 28, 2022

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Cardene In 0.86% Sodium Chloride In Plastic Container patents expire, and what generic alternatives are available?

Cardene In 0.86% Sodium Chloride In Plastic Container is a drug marketed by Chiesi and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-three patent family members in eleven countries.

The generic ingredient in CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cardene In 0.86% Sodium Chloride In Plastic Container

A generic version of CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.

  Sign up for a Free Trial

Summary for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER
Drug patent expirations by year for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER
Recent Clinical Trials for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Neurological Disorders and Stroke (NINDS)Phase 2
University of CincinnatiPhase 2
Vanderbilt University Medical CenterPhase 2

See all CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

US Patents and Regulatory Information for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER is protected by five US patents.

Patents protecting CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

Pre-mixed, ready-to-use pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pre-mixed, ready-to-use pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF

Pre-mixed, ready-to-use pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Chiesi CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Chiesi CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER nicardipine hydrochloride INJECTABLE;INTRAVENOUS 019734-003 Jul 31, 2008 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

See the table below for patents covering CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER around the world.

Country Patent Number Title Estimated Expiration
Japan 2009534409 See Plans and Pricing
Japan S5720950 See Plans and Pricing
Sweden 410451 SETT ATT FRAMSTELLA EN 2,6-DI-LEGRE ALKYL-4-SUBSTITUERAD FENYL-1,4-DIHYDROPYSIDIN-3-KARBOXYLSYRAAMINOALKYLESTER See Plans and Pricing
China 101484136 Pre-mixed, ready-to-use pharmaceutical compositions See Plans and Pricing
New Zealand 572225 Pre-mixed pharmaceutical compositions comprising nicardipine, a tonicity agent, and a buffer See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
AstraZeneca
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.